- Home
- NRIX vs BCX Comparison
NRIX vs BCX Comparison
Compare NRIX & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- BCX
- Stock Information
- Founded
- NRIX 2009
- BCX 2011
- Country
- NRIX United States
- BCX United States
- Employees
- NRIX N/A
- BCX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- NRIX Health Care
- BCX Finance
- Exchange
- NRIX Nasdaq
- BCX Nasdaq
- Market Cap
- NRIX 750.4M
- BCX 750.9M
- IPO Year
- NRIX 2020
- BCX N/A
- Fundamental
- Price
- NRIX $16.85
- BCX $9.77
- Analyst Decision
- NRIX Strong Buy
- BCX
- Analyst Count
- NRIX 14
- BCX 0
- Target Price
- NRIX $26.29
- BCX N/A
- AVG Volume (30 Days)
- NRIX 1.8M
- BCX 370.6K
- Earning Date
- NRIX 10-09-2025
- BCX 01-01-0001
- Dividend Yield
- NRIX N/A
- BCX 6.99%
- EPS Growth
- NRIX N/A
- BCX N/A
- EPS
- NRIX N/A
- BCX N/A
- Revenue
- NRIX $83,687,000.00
- BCX N/A
- Revenue This Year
- NRIX $58.48
- BCX N/A
- Revenue Next Year
- NRIX N/A
- BCX N/A
- P/E Ratio
- NRIX N/A
- BCX N/A
- Revenue Growth
- NRIX 48.32
- BCX N/A
- 52 Week Low
- NRIX $8.18
- BCX $8.25
- 52 Week High
- NRIX $23.09
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- NRIX 80.15
- BCX 39.79
- Support Level
- NRIX $12.43
- BCX $9.70
- Resistance Level
- NRIX $13.43
- BCX $9.97
- Average True Range (ATR)
- NRIX 0.97
- BCX 0.15
- MACD
- NRIX 0.32
- BCX -0.03
- Stochastic Oscillator
- NRIX 98.68
- BCX 8.96
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.